CNS Pharmaceuticals (CNSP) said Tuesday it has acquired from Cortice Biosciences orphan drug designation for late stage abeotaxane TPI 287 as a potential treatment for glioblastoma multiforme.
The company said it aims to begin enrolling patients for a phase 2 study around the end of this year. Clinical data from a phase 1 trial showed that TPI 287 has the potential to cross the blood brain barrier and treat central nervous system tumors, according to the company.
TPI 287 was previously granted orphan drug designation by the US Food and Drug Administration in gliomas, pediatric neuroblastoma, and progressive supranuclear palsy, the company said.
The company's shares surged past 120% in recent Tuesday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。